Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

No evidence of increased adverse drug re

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

✍ Rebecca L. Roberts; Roger T. Mulder; Peter R. Joyce; Suzanne E. Luty; Martin A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

## Abstract The polymorphic enzyme cytochrome P450 CYP2D6 is involved in the metabolism of many antidepressants, including nortriptyline and fluoxetine. Some 7%–10% Caucasians have inactivating mutations in both alleles of the __CYP2D6__ gene, and are referred to as poor metabolizers (PMs). Several